Clinical Trial Update: Pharmacokinetic (PK) Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study of subcutaneously administered homoharringtonine (omacetaxine mepesuccinate) in patients with advanced solid and hematologic tumor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Cancer
• Solid Tumors

Drugs mentioned

• Synribo (omacetaxine mepesuccinate)

Snippet

Sponsor: ChemGenex Pharmaceuticals | Conditions: Hematologic Tumors | Phase 1 | Status: COMPLETED